BlackRock
HOWL icon

BlackRock’s Werewolf Therapeutics HOWL Stock Holding History

BlackRock’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.6K Sell
101,573
-35
-0% -$21 ﹤0.01% 5251
2026
Q1 		$84.6K Sell
101,608
-35
-0% -$24 ﹤0.01% 4996
2025
Q4 		$64.4K Buy
101,643
+320
+0.3% +$389 ﹤0.01% 4997
2025
Q3 		$200K Sell
101,323
-260,660
-72% -$357K ﹤0.01% 4681
2025
Q2 		$395K Sell
361,983
-1,309,872
-78% -$1.35M ﹤0.01% 4502
2025
Q1 		$1.63M Sell
1,671,855
-28,577
-2% -$37.4K ﹤0.01% 4054
2024
Q4 		$2.52M Buy
1,700,432
+63,382
+4% +$129K ﹤0.01% 3972
2024
Q3 		$3.47M Buy
1,637,050
+49,326
+3% +$112K ﹤0.01% 3838
2024
Q2 		$3.87M Buy
1,587,724
+1,422,932
+863% +$6.83M ﹤0.01% 3780
2024
Q1 		$1.07M Buy
164,792
+92,564
+128% +$539K ﹤0.01% 4184
2023
Q4 		$279K Sell
72,228
-4,885
-6% -$12.5K ﹤0.01% 4558
2023
Q3 		$165K Buy
77,113
+3,132
+4% +$8.63K ﹤0.01% 4727
2023
Q2 		$226K Buy
73,981
+34,987
+90% +$98.5K ﹤0.01% 4703
2023
Q1 		$101K Buy
38,994
+456
+1% +$1.36K ﹤0.01% 4950
2022
Q4 		$79K Sell
38,538
-109,471
-74% -$286K ﹤0.01% 5110
2022
Q3 		$668K Sell
148,009
-35,948
-20% -$195K ﹤0.01% 4629
2022
Q2 		$752K Sell
183,957
-1,099,588
-86% -$5.02M ﹤0.01% 4649
2022
Q1 		$5.65M Buy
1,283,545
+7,337
+0.6% +$51.4K ﹤0.01% 3892
2021
Q4 		$15.2M Buy
1,276,208
+906,247
+245% +$13.7M ﹤0.01% 3432
2021
Q3 		$6.35M Buy
369,961
+4,098
+1% +$69.9K ﹤0.01% 3865
2021
Q2 		$6.38M Buy
+365,863
New +$5.01M ﹤0.01% 3799

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
VA
Verdad Advisers Boston, Massachusetts $104M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock's HOWL Position: Q2 2026 in Review

BlackRock reduced its Werewolf Therapeutics (HOWL) stake by 0.03% in Q2 2026, selling an estimated $21 and leaving 101,573 shares worth $36.6K. The position accounts for ﹤0.01% of the portfolio, ranked #5251.

BlackRock first reported a position in HOWL in Q2 2021 and has held it in 21 quarters since. The position peaked at $15.2M in Q4 2021. 45 funds tracked by Wall St. Rank hold HOWL as of Q2 2026.

  • BlackRock held 101,573 shares of Werewolf Therapeutics worth $36.6K as of Q2 2026.
  • BlackRock sold 35 Werewolf Therapeutics shares in Q2 2026, an estimated $21.
  • Werewolf Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5251 holding.
  • BlackRock first reported a position in Werewolf Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • BlackRock's Werewolf Therapeutics position peaked at $15.2M in Q4 2021.
  • 45 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.